Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Market price (% of par)
-
87.6%
-
Total 13F principal
-
$479,836,374
-
Principal change
-
-$20,289,863
-
Total reported market value
-
$423,793,862
-
Number of holders
-
47
-
Value change
-
-$14,928,946
-
Number of buys
-
22
-
Number of sells
-
17
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2020
As of 30 Jun 2020,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 was held by
47 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$479,836,374
in principal (par value) of the bond.
The largest 10 bondholders included
STEELHEAD PARTNERS LLC, CANYON CAPITAL ADVISORS LLC, Allianz Asset Management GmbH, UBS ASSET MANAGEMENT AMERICAS INC, ADVENT CAPITAL MANAGEMENT /DE/, WOLVERINE ASSET MANAGEMENT LLC, Davidson Kempner Capital Management LP, OAKTREE CAPITAL MANAGEMENT LP, GOLDMAN SACHS GROUP INC, and SYMPHONY ASSET MANAGEMENT LLC.
This page lists
47
institutional bondholders reporting positions
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.